- Home
- TCOM vs ARGX Comparison
TCOM vs ARGX Comparison
Compare TCOM & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCOM
- ARGX
- Stock Information
- Founded
- TCOM 1999
- ARGX 2008
- Country
- TCOM Singapore
- ARGX Netherlands
- Employees
- TCOM N/A
- ARGX N/A
- Industry
- TCOM Hotels/Resorts
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCOM Consumer Discretionary
- ARGX Health Care
- Exchange
- TCOM Nasdaq
- ARGX Nasdaq
- Market Cap
- TCOM 42.1B
- ARGX 37.3B
- IPO Year
- TCOM 2003
- ARGX 2017
- Fundamental
- Price
- TCOM $72.95
- ARGX $634.00
- Analyst Decision
- TCOM Strong Buy
- ARGX Strong Buy
- Analyst Count
- TCOM 10
- ARGX 21
- Target Price
- TCOM $74.18
- ARGX $630.42
- AVG Volume (30 Days)
- TCOM 3.8M
- ARGX 293.9K
- Earning Date
- TCOM 11-18-2024
- ARGX 10-31-2024
- Dividend Yield
- TCOM N/A
- ARGX N/A
- EPS Growth
- TCOM 50.61
- ARGX N/A
- EPS
- TCOM 3.40
- ARGX N/A
- Revenue
- TCOM $7,252,833,407.00
- ARGX $1,908,659,000.00
- Revenue This Year
- TCOM $19.96
- ARGX $61.99
- Revenue Next Year
- TCOM $15.03
- ARGX $42.48
- P/E Ratio
- TCOM $21.32
- ARGX N/A
- Revenue Growth
- TCOM 29.74
- ARGX 85.56
- 52 Week Low
- TCOM $33.67
- ARGX $327.73
- 52 Week High
- TCOM $77.18
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- TCOM 61.46
- ARGX 65.32
- Support Level
- TCOM $71.32
- ARGX $602.44
- Resistance Level
- TCOM $74.70
- ARGX $644.97
- Average True Range (ATR)
- TCOM 1.62
- ARGX 12.26
- MACD
- TCOM 0.43
- ARGX 0.73
- Stochastic Oscillator
- TCOM 69.34
- ARGX 78.40
About TCOM Trip.com Group Limited
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from its online platform, but the company also maintains offline call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.